Graham P Bailey

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint The value of juvenile animal studies "What have we learned from preclinical juvenile toxicity studies? II"
    Graham P Bailey
    Toxicology Pathology, Drug Safety Sciences, Janssen Research and Development, Turnhoutseweg 30, Beerse, Belgium
    Birth Defects Res B Dev Reprod Toxicol 92:273-91. 2011
  2. doi request reprint What have we learned from pre-clinical juvenile toxicity studies?
    Graham P Bailey
    Toxicology Pathology Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, Beerse, Belgium
    Reprod Toxicol 28:226-9. 2009
  3. doi request reprint Pre- and postnatal developmental toxicity study design for pharmaceuticals
    Graham P Bailey
    Johnson and Johnson PRD, Janssen Pharmaceutica, Beerse, Belgium
    Birth Defects Res B Dev Reprod Toxicol 86:437-45. 2009
  4. doi request reprint Real life juvenile toxicity case studies: the good, the bad and the ugly
    Luc De Schaepdrijver
    Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Reprod Toxicol 26:54-5. 2008
  5. doi request reprint The ontogeny of drug metabolizing enzymes and transporters in the rat
    Loeckie De Zwart
    Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, B 2340 Beerse, Belgium
    Reprod Toxicol 26:220-30. 2008

Detail Information

Publications5

  1. doi request reprint The value of juvenile animal studies "What have we learned from preclinical juvenile toxicity studies? II"
    Graham P Bailey
    Toxicology Pathology, Drug Safety Sciences, Janssen Research and Development, Turnhoutseweg 30, Beerse, Belgium
    Birth Defects Res B Dev Reprod Toxicol 92:273-91. 2011
    ..Only with appropriate designs can we adequately identify safety or pharmacokinetic issues, suggest clinical endpoints, and contribute to the product label...
  2. doi request reprint What have we learned from pre-clinical juvenile toxicity studies?
    Graham P Bailey
    Toxicology Pathology Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, Beerse, Belgium
    Reprod Toxicol 28:226-9. 2009
    ..Only when using appropriately designed studies can we adequately identify potential safety or pharmacokinetic issues, suggest additional clinical endpoints and/or contribute to the product label...
  3. doi request reprint Pre- and postnatal developmental toxicity study design for pharmaceuticals
    Graham P Bailey
    Johnson and Johnson PRD, Janssen Pharmaceutica, Beerse, Belgium
    Birth Defects Res B Dev Reprod Toxicol 86:437-45. 2009
    ..The details described herein will assist all laboratories performing these studies, individuals who need to plan for the studies, and regulatory agencies that ultimately review these studies...
  4. doi request reprint Real life juvenile toxicity case studies: the good, the bad and the ugly
    Luc De Schaepdrijver
    Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Reprod Toxicol 26:54-5. 2008
    ..As the knowledge from juvenile animal studies in various species grows, a better understanding of the significance/relevance of findings will be achieved...
  5. doi request reprint The ontogeny of drug metabolizing enzymes and transporters in the rat
    Loeckie De Zwart
    Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, B 2340 Beerse, Belgium
    Reprod Toxicol 26:220-30. 2008
    ..Consideration of the ontogeny of metabolizing enzymes and transporters may improve the design and interpretation of results of toxicity studies in juvenile animals...